A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.